Based on the clinical results, Marinus plans to advance the studies into the next phase of development to evaluate ganaxolone IV and oral dose regimens. The company also expects to present the data from these studies in 1H19.
Postpartum depression is a mood disorder that affects about 15% of women within the first year following childbirth. Common symptoms include feelings of extreme sadness, hopelessness, suicidal ideation, anxiety and fatigue. So far there are no approved treatments for PPD, but the most common treatments are psychotherapy and antidepressants.
Last Tuesday, the Radnor, Pennsylvania-based pharma company, presented data from its ganaxolone Phase 2 clinical trial for the treatment of pediatric genetic epilepsies at the American Epilepsy Society (AES) Annual Meeting. Marinus stated that ganaxolone showed sustained, long-term effectiveness in treating children with CDD, a refractory form of pediatric epilepsy.
Proteostasis Therapeutics stock skyrockets on positive trial results
MRNS stock had dropped 25% in the past three months and 40% in the past one year. The stock closed down 2.64% at $5.17 on Friday.